Despite a market landscape that could be politely described as “politically adventurous,” global M&A activity entered 2026 with enviable momentum. In the first quarter alone, dealmakers put pen to paper—or, more accurately, data room to data room—on transactions totaling a staggering $1.4…
French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…
Eli Lilly (LLY) has once again muscled its way to the top of the healthcare league tables, with its stock climbing as investors double down on the idea that obesity drugs are less a fad and more a new asset class. The…
Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…
Meta’s agreed purchase of AI agent startup Manus for more than $2 billion reads like a late‑cycle plot twist: the social media giant that rebranded around the metaverse is now buying an AI “do‑it‑for‑you” brain to justify all that spending. In Wall…
